Q-omics provides the consensus-scored STX2 profile across patient tissues and cancer cell-line models. STX2 expression is associated with patient survival in 30 of 34 cancer types, with the highest sampling consensus in LUSC. Among the 18 cancer types available for tumor–normal comparison, STX2 is differentially expressed in 15, with the highest sampling consensus in HNSC. Additionally, STX2 protein abundance shows 30,233 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight LUSC, HNSC, and LSCC as cancer lineages where STX2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for STX2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes STX2 survival associations across molecular data types. STX2 RNA expression shows survival associations in the most cancer types (30), followed by mutation status (5) and mass-spec protein abundance (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible STX2 RNA expression–survival associations across cancer types. High STX2 expression shows unfavorable associations in LUSC, ACC, UVM, LGG, CESC and MESO. The LUSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUSC as the clearest survival context for STX2 RNA expression.
This table summarizes STX2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 11. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for STX2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. STX2 shows lower tumor expression in THCA, LUSC, KICH and LUAD and higher tumor expression in HNSC and KIRC. The HNSC box plot shows higher STX2 RNA expression in tumor versus normal tissue (log2 FC = +1.494, t-test p < 0.001).
This table shows molecular features associated with STX2 in patient tissues and cancer cell lines. In patient samples, STX2 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, STX2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in SKIN and LARGE_INTESTINE.
